[
  {
    "ts": null,
    "headline": "TREMFYA® (guselkumab) achieves U.S. approval for subcutaneous induction in adults with ulcerative colitis, now the first and only IL-23 inhibitor with a fully subcutaneous regimen",
    "summary": "Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has approved a subcutaneous (SC) induction regimen of TREMFYA® (guselkumab) for the treatment of adults with moderately to severely active ulcerative colitis (UC). With this approval, TREMFYA® is the first and only IL-23 inhibitor to offer both SC and intravenous (IV) induction options for the treatment of UC and Crohn's disease (CD), which combined affect approximately three million Americans.1 TREMFY",
    "url": "https://finnhub.io/api/news?id=3ba8d24d27e2c67686d6716e6fa9be7c9840a7cab514bdee4d129f935931f3ad",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758320880,
      "headline": "TREMFYA® (guselkumab) achieves U.S. approval for subcutaneous induction in adults with ulcerative colitis, now the first and only IL-23 inhibitor with a fully subcutaneous regimen",
      "id": 136823459,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has approved a subcutaneous (SC) induction regimen of TREMFYA® (guselkumab) for the treatment of adults with moderately to severely active ulcerative colitis (UC). With this approval, TREMFYA® is the first and only IL-23 inhibitor to offer both SC and intravenous (IV) induction options for the treatment of UC and Crohn's disease (CD), which combined affect approximately three million Americans.1 TREMFY",
      "url": "https://finnhub.io/api/news?id=3ba8d24d27e2c67686d6716e6fa9be7c9840a7cab514bdee4d129f935931f3ad"
    }
  },
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Mixed Late Afternoon",
    "summary": "Health care stocks were mixed late Friday afternoon, with the NYSE Health Care Index easing 0.1% and",
    "url": "https://finnhub.io/api/news?id=ccaec67fa21b9adcb24ec0acf9de8ee6c6248edb7bed7f983e333b3b6e90cb6c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758315770,
      "headline": "Sector Update: Health Care Stocks Mixed Late Afternoon",
      "id": 136823460,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Health care stocks were mixed late Friday afternoon, with the NYSE Health Care Index easing 0.1% and",
      "url": "https://finnhub.io/api/news?id=ccaec67fa21b9adcb24ec0acf9de8ee6c6248edb7bed7f983e333b3b6e90cb6c"
    }
  },
  {
    "ts": null,
    "headline": "Can Regeneron Change The Paradigm In Multiple Myeloma — And Undercut J&J?",
    "summary": "Regeneron unveiled what it calls \"paradigm-shifting\" test results for a drug that could prevent patients from developing multiple myeloma.",
    "url": "https://finnhub.io/api/news?id=dcf977a2bc6e2599d37a000455caf112778cb173385a46670d73969b3b8ad19f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758305734,
      "headline": "Can Regeneron Change The Paradigm In Multiple Myeloma — And Undercut J&J?",
      "id": 136820664,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Regeneron unveiled what it calls \"paradigm-shifting\" test results for a drug that could prevent patients from developing multiple myeloma.",
      "url": "https://finnhub.io/api/news?id=dcf977a2bc6e2599d37a000455caf112778cb173385a46670d73969b3b8ad19f"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson Gets Approval for Subcutaneous Induction Option for Ulcerative Colitis",
    "summary": "Johnson & Johnson Gets Approval for Subcutaneous Induction Option for Ulcerative Colitis",
    "url": "https://finnhub.io/api/news?id=c8bcc2663f793c509e8f2db804a18b7142d7bd823bae1f04e9fa94c6aaa751f5",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758305580,
      "headline": "Johnson & Johnson Gets Approval for Subcutaneous Induction Option for Ulcerative Colitis",
      "id": 136867514,
      "image": "",
      "related": "JNJ",
      "source": "MarketWatch",
      "summary": "Johnson & Johnson Gets Approval for Subcutaneous Induction Option for Ulcerative Colitis",
      "url": "https://finnhub.io/api/news?id=c8bcc2663f793c509e8f2db804a18b7142d7bd823bae1f04e9fa94c6aaa751f5"
    }
  },
  {
    "ts": null,
    "headline": "J&J’s newly diagnosed multiple myeloma induction combo elicits 100% OR",
    "summary": "In MRD-evaluable patients, 100% achieved MRD negativity after six cycles of treatment.",
    "url": "https://finnhub.io/api/news?id=4625a55f71c2524ea4c3499685f710a14a4941b2777f900af20831dad4aebb89",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758301591,
      "headline": "J&J’s newly diagnosed multiple myeloma induction combo elicits 100% OR",
      "id": 136820665,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "In MRD-evaluable patients, 100% achieved MRD negativity after six cycles of treatment.",
      "url": "https://finnhub.io/api/news?id=4625a55f71c2524ea4c3499685f710a14a4941b2777f900af20831dad4aebb89"
    }
  },
  {
    "ts": null,
    "headline": "Boost Your Portfolio With These Top-Ranked ETFs",
    "summary": "With the Fed's first 2025 rate cut and upgraded growth outlook, ETFs in tech, financials, industrials and health care could benefit from momentum.",
    "url": "https://finnhub.io/api/news?id=c3a16726b91d0b08996b35a01e7c94129896f7eb5a7275e118581c668933c7f2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758301380,
      "headline": "Boost Your Portfolio With These Top-Ranked ETFs",
      "id": 136820651,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "With the Fed's first 2025 rate cut and upgraded growth outlook, ETFs in tech, financials, industrials and health care could benefit from momentum.",
      "url": "https://finnhub.io/api/news?id=c3a16726b91d0b08996b35a01e7c94129896f7eb5a7275e118581c668933c7f2"
    }
  },
  {
    "ts": null,
    "headline": "Can MRK's New Drugs Drive Long-Term Growth Amid Looming Keytruda LOE?",
    "summary": "Merck eyes new launches like Capvaxive and Winrevair, among others, to drive long-term growth as Keytruda nears loss of exclusivity.",
    "url": "https://finnhub.io/api/news?id=62f099d987968db996f619d5b0762dcec0570e964c7089f4f358445834aa9c38",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758300780,
      "headline": "Can MRK's New Drugs Drive Long-Term Growth Amid Looming Keytruda LOE?",
      "id": 136820667,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Merck eyes new launches like Capvaxive and Winrevair, among others, to drive long-term growth as Keytruda nears loss of exclusivity.",
      "url": "https://finnhub.io/api/news?id=62f099d987968db996f619d5b0762dcec0570e964c7089f4f358445834aa9c38"
    }
  },
  {
    "ts": null,
    "headline": "TECVAYLI® and DARZALEX FASPRO®-based induction treatment demonstrates promising rates and depths of response in transplant-eligible patients with newly diagnosed multiple myeloma",
    "summary": "Johnson & Johnson (NYSE:JNJ) today announced that an investigational immune-based induction regimen with TECVAYLI® (teclistamab-cqyv) and DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) demonstrated meaningful clinical efficacy in transplant-eligible (TE) patients with newly diagnosed multiple myeloma (NDMM).",
    "url": "https://finnhub.io/api/news?id=d1dbb4f5e7a36fa3d4333281593532fa829bde1344f47cd13a41e041a9544b64",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758288600,
      "headline": "TECVAYLI® and DARZALEX FASPRO®-based induction treatment demonstrates promising rates and depths of response in transplant-eligible patients with newly diagnosed multiple myeloma",
      "id": 136818217,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE:JNJ) today announced that an investigational immune-based induction regimen with TECVAYLI® (teclistamab-cqyv) and DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) demonstrated meaningful clinical efficacy in transplant-eligible (TE) patients with newly diagnosed multiple myeloma (NDMM).",
      "url": "https://finnhub.io/api/news?id=d1dbb4f5e7a36fa3d4333281593532fa829bde1344f47cd13a41e041a9544b64"
    }
  },
  {
    "ts": null,
    "headline": "Top Wide-Moat Stocks Worth a Look for Sustainable Growth",
    "summary": "MSFT, JNJ, NKE and SPGI use strong moats to fend off rivals and deliver consistent returns amid market shifts.",
    "url": "https://finnhub.io/api/news?id=812f7a2ea0297acce20943de70f0991ea053c72c3859dc3e495d1426bda12213",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758283620,
      "headline": "Top Wide-Moat Stocks Worth a Look for Sustainable Growth",
      "id": 136818218,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "MSFT, JNJ, NKE and SPGI use strong moats to fend off rivals and deliver consistent returns amid market shifts.",
      "url": "https://finnhub.io/api/news?id=812f7a2ea0297acce20943de70f0991ea053c72c3859dc3e495d1426bda12213"
    }
  },
  {
    "ts": null,
    "headline": "CHMP recommends approval of J&J's nipocalimab for myasthenia gravis",
    "summary": "Johnson & Johnson announced on Friday that the Committee for Medicinal Products for Human Use of the European Medicines Agency had adopted a positive opinion recommending the approval of nipocalimab...",
    "url": "https://finnhub.io/api/news?id=91ec45dc0e2c9d29880ba051120cc123d7878809556de7612f0056f47cd9e9ec",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758279251,
      "headline": "CHMP recommends approval of J&J's nipocalimab for myasthenia gravis",
      "id": 136819763,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "Johnson & Johnson announced on Friday that the Committee for Medicinal Products for Human Use of the European Medicines Agency had adopted a positive opinion recommending the approval of nipocalimab...",
      "url": "https://finnhub.io/api/news?id=91ec45dc0e2c9d29880ba051120cc123d7878809556de7612f0056f47cd9e9ec"
    }
  },
  {
    "ts": null,
    "headline": "Apple, Amgen share gains contribute to Dow's 118-point jump",
    "summary": "Apple, Amgen share gains contribute to Dow's 118-point jump",
    "url": "https://finnhub.io/api/news?id=00aacf4e165888e38438e9153592f07644b1a3a185a76a0cf2d17bc30994a5e8",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758275520,
      "headline": "Apple, Amgen share gains contribute to Dow's 118-point jump",
      "id": 136867515,
      "image": "",
      "related": "JNJ",
      "source": "MarketWatch",
      "summary": "Apple, Amgen share gains contribute to Dow's 118-point jump",
      "url": "https://finnhub.io/api/news?id=00aacf4e165888e38438e9153592f07644b1a3a185a76a0cf2d17bc30994a5e8"
    }
  },
  {
    "ts": null,
    "headline": "J&J’s IVL market dominance to continue with launch of Javelin catheter in Europe",
    "summary": "Shockwave Medical has been the only major player in the IVL market since 2015.",
    "url": "https://finnhub.io/api/news?id=456033f10b1b193028e38e549eb8e3eab566c128d45bc263a2d6fefb02615c21",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758274794,
      "headline": "J&J’s IVL market dominance to continue with launch of Javelin catheter in Europe",
      "id": 136818219,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Shockwave Medical has been the only major player in the IVL market since 2015.",
      "url": "https://finnhub.io/api/news?id=456033f10b1b193028e38e549eb8e3eab566c128d45bc263a2d6fefb02615c21"
    }
  },
  {
    "ts": null,
    "headline": "J&J presents promising results in multiple myeloma",
    "summary": "Johnson & Johnson has announced that the experimental combination of Tecvayli and Darzalex Faspro showed significant clinical efficacy in newly diagnosed patients with multiple myeloma who were...",
    "url": "https://finnhub.io/api/news?id=ff86eded296ac2b12889bfeae3c2061055757dd2a08d4dd80be49455e69d0210",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758274758,
      "headline": "J&J presents promising results in multiple myeloma",
      "id": 136817823,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "Johnson & Johnson has announced that the experimental combination of Tecvayli and Darzalex Faspro showed significant clinical efficacy in newly diagnosed patients with multiple myeloma who were...",
      "url": "https://finnhub.io/api/news?id=ff86eded296ac2b12889bfeae3c2061055757dd2a08d4dd80be49455e69d0210"
    }
  },
  {
    "ts": null,
    "headline": "AstraZeneca: Consistent Growth And Upcoming Catalysts Make This A Buy",
    "summary": "AstraZeneca is a leading global pharmaceutical company with strong growth in oncology, diversified revenues, and a robust pipeline. Click to read why AZN is a Buy.",
    "url": "https://finnhub.io/api/news?id=63c9970de83b73de6359dad980ea68cde4507b9840f7c6dc916a402fc1a3dead",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758274254,
      "headline": "AstraZeneca: Consistent Growth And Upcoming Catalysts Make This A Buy",
      "id": 136817825,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1250576655/image_1250576655.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "AstraZeneca is a leading global pharmaceutical company with strong growth in oncology, diversified revenues, and a robust pipeline. Click to read why AZN is a Buy.",
      "url": "https://finnhub.io/api/news?id=63c9970de83b73de6359dad980ea68cde4507b9840f7c6dc916a402fc1a3dead"
    }
  },
  {
    "ts": null,
    "headline": "Jim Cramer on Johnson & Johnson: “Very Rare Triple-A Balance Sheet”",
    "summary": "Johnson & Johnson (NYSE:JNJ) is one of the stocks Jim Cramer commented on. Cramer discussed the stock’s momentum during the episode, as he said: “As of last night’s close, JNJ was the 10th best performing healthcare stock in the entire S&P 500, up 21.5% for the year. Now, if you’ve been paying attention to this […]",
    "url": "https://finnhub.io/api/news?id=b99cb8d3d821570ff6cf190925d1963753bcf3566d34174f5083fad460fd9d8b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758255961,
      "headline": "Jim Cramer on Johnson & Johnson: “Very Rare Triple-A Balance Sheet”",
      "id": 136818220,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE:JNJ) is one of the stocks Jim Cramer commented on. Cramer discussed the stock’s momentum during the episode, as he said: “As of last night’s close, JNJ was the 10th best performing healthcare stock in the entire S&P 500, up 21.5% for the year. Now, if you’ve been paying attention to this […]",
      "url": "https://finnhub.io/api/news?id=b99cb8d3d821570ff6cf190925d1963753bcf3566d34174f5083fad460fd9d8b"
    }
  }
]